Copyright Reports & Markets. All rights reserved.

Global Viral Vector and Plasmid DNA Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Viral Vector and Plasmid DNA by Type
    • 1.3.1 Overview: Global Viral Vector and Plasmid DNA Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Viral Vector and Plasmid DNA Consumption Value Market Share by Type in 2025
    • 1.3.3 AAV
    • 1.3.4 Lentiviruses
    • 1.3.5 Retroviruses
    • 1.3.6 Adenoviruses
    • 1.3.7 DNA Plasmids
    • 1.3.8 Other
  • 1.4 Global Viral Vector and Plasmid DNA Market by Application
    • 1.4.1 Overview: Global Viral Vector and Plasmid DNA Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Pharmaceutical and Biopharmaceutical Companies
    • 1.4.3 Academics and Research Institutes
  • 1.5 Global Viral Vector and Plasmid DNA Market Size & Forecast
  • 1.6 Global Viral Vector and Plasmid DNA Market Size and Forecast by Region
    • 1.6.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Viral Vector and Plasmid DNA Market Size by Region, (2021-2032)
    • 1.6.3 North America Viral Vector and Plasmid DNA Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Viral Vector and Plasmid DNA Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Viral Vector and Plasmid DNA Market Size and Prospect (2021-2032)
    • 1.6.6 South America Viral Vector and Plasmid DNA Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Viral Vector and Plasmid DNA Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Thermo Fisher Scientific
    • 2.1.1 Thermo Fisher Scientific Details
    • 2.1.2 Thermo Fisher Scientific Major Business
    • 2.1.3 Thermo Fisher Scientific Viral Vector and Plasmid DNA Product and Solutions
    • 2.1.4 Thermo Fisher Scientific Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.2 Lonza
    • 2.2.1 Lonza Details
    • 2.2.2 Lonza Major Business
    • 2.2.3 Lonza Viral Vector and Plasmid DNA Product and Solutions
    • 2.2.4 Lonza Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Lonza Recent Developments and Future Plans
  • 2.3 Azenta Life Sciences
    • 2.3.1 Azenta Life Sciences Details
    • 2.3.2 Azenta Life Sciences Major Business
    • 2.3.3 Azenta Life Sciences Viral Vector and Plasmid DNA Product and Solutions
    • 2.3.4 Azenta Life Sciences Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Azenta Life Sciences Recent Developments and Future Plans
  • 2.4 Revvity
    • 2.4.1 Revvity Details
    • 2.4.2 Revvity Major Business
    • 2.4.3 Revvity Viral Vector and Plasmid DNA Product and Solutions
    • 2.4.4 Revvity Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Revvity Recent Developments and Future Plans
  • 2.5 VectorBuilder
    • 2.5.1 VectorBuilder Details
    • 2.5.2 VectorBuilder Major Business
    • 2.5.3 VectorBuilder Viral Vector and Plasmid DNA Product and Solutions
    • 2.5.4 VectorBuilder Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 VectorBuilder Recent Developments and Future Plans
  • 2.6 Takara Bio
    • 2.6.1 Takara Bio Details
    • 2.6.2 Takara Bio Major Business
    • 2.6.3 Takara Bio Viral Vector and Plasmid DNA Product and Solutions
    • 2.6.4 Takara Bio Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Takara Bio Recent Developments and Future Plans
  • 2.7 GenScript Biotech
    • 2.7.1 GenScript Biotech Details
    • 2.7.2 GenScript Biotech Major Business
    • 2.7.3 GenScript Biotech Viral Vector and Plasmid DNA Product and Solutions
    • 2.7.4 GenScript Biotech Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 GenScript Biotech Recent Developments and Future Plans
  • 2.8 Gene Chem
    • 2.8.1 Gene Chem Details
    • 2.8.2 Gene Chem Major Business
    • 2.8.3 Gene Chem Viral Vector and Plasmid DNA Product and Solutions
    • 2.8.4 Gene Chem Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Gene Chem Recent Developments and Future Plans
  • 2.9 Geno Meditech
    • 2.9.1 Geno Meditech Details
    • 2.9.2 Geno Meditech Major Business
    • 2.9.3 Geno Meditech Viral Vector and Plasmid DNA Product and Solutions
    • 2.9.4 Geno Meditech Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Geno Meditech Recent Developments and Future Plans
  • 2.10 PackGene Biotech
    • 2.10.1 PackGene Biotech Details
    • 2.10.2 PackGene Biotech Major Business
    • 2.10.3 PackGene Biotech Viral Vector and Plasmid DNA Product and Solutions
    • 2.10.4 PackGene Biotech Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 PackGene Biotech Recent Developments and Future Plans
  • 2.11 VIROVEK
    • 2.11.1 VIROVEK Details
    • 2.11.2 VIROVEK Major Business
    • 2.11.3 VIROVEK Viral Vector and Plasmid DNA Product and Solutions
    • 2.11.4 VIROVEK Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 VIROVEK Recent Developments and Future Plans
  • 2.12 OriGen
    • 2.12.1 OriGen Details
    • 2.12.2 OriGen Major Business
    • 2.12.3 OriGen Viral Vector and Plasmid DNA Product and Solutions
    • 2.12.4 OriGen Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 OriGen Recent Developments and Future Plans
  • 2.13 Vector BioLabs
    • 2.13.1 Vector BioLabs Details
    • 2.13.2 Vector BioLabs Major Business
    • 2.13.3 Vector BioLabs Viral Vector and Plasmid DNA Product and Solutions
    • 2.13.4 Vector BioLabs Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Vector BioLabs Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Viral Vector and Plasmid DNA Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Viral Vector and Plasmid DNA by Company Revenue
    • 3.2.2 Top 3 Viral Vector and Plasmid DNA Players Market Share in 2025
    • 3.2.3 Top 6 Viral Vector and Plasmid DNA Players Market Share in 2025
  • 3.3 Viral Vector and Plasmid DNA Market: Overall Company Footprint Analysis
    • 3.3.1 Viral Vector and Plasmid DNA Market: Region Footprint
    • 3.3.2 Viral Vector and Plasmid DNA Market: Company Product Type Footprint
    • 3.3.3 Viral Vector and Plasmid DNA Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Viral Vector and Plasmid DNA Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Viral Vector and Plasmid DNA Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Viral Vector and Plasmid DNA Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Viral Vector and Plasmid DNA Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Viral Vector and Plasmid DNA Consumption Value by Type (2021-2032)
  • 6.2 North America Viral Vector and Plasmid DNA Market Size by Application (2021-2032)
  • 6.3 North America Viral Vector and Plasmid DNA Market Size by Country
    • 6.3.1 North America Viral Vector and Plasmid DNA Consumption Value by Country (2021-2032)
    • 6.3.2 United States Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Viral Vector and Plasmid DNA Consumption Value by Type (2021-2032)
  • 7.2 Europe Viral Vector and Plasmid DNA Consumption Value by Application (2021-2032)
  • 7.3 Europe Viral Vector and Plasmid DNA Market Size by Country
    • 7.3.1 Europe Viral Vector and Plasmid DNA Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 7.3.3 France Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region
    • 8.3.1 Asia-Pacific Viral Vector and Plasmid DNA Consumption Value by Region (2021-2032)
    • 8.3.2 China Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 8.3.5 India Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Viral Vector and Plasmid DNA Consumption Value by Type (2021-2032)
  • 9.2 South America Viral Vector and Plasmid DNA Consumption Value by Application (2021-2032)
  • 9.3 South America Viral Vector and Plasmid DNA Market Size by Country
    • 9.3.1 South America Viral Vector and Plasmid DNA Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country
    • 10.3.1 Middle East & Africa Viral Vector and Plasmid DNA Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Viral Vector and Plasmid DNA Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Viral Vector and Plasmid DNA Market Drivers
  • 11.2 Viral Vector and Plasmid DNA Market Restraints
  • 11.3 Viral Vector and Plasmid DNA Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Viral Vector and Plasmid DNA Industry Chain
  • 12.2 Viral Vector and Plasmid DNA Upstream Analysis
  • 12.3 Viral Vector and Plasmid DNA Midstream Analysis
  • 12.4 Viral Vector and Plasmid DNA Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Viral Vector and Plasmid DNA market size was valued at US$ 884 million in 2025 and is forecast to a readjusted size of US$ 5302 million by 2032 with a CAGR of 29.5% during review period.
    Viral Vector and Plasmid DNA Manufacturing refers to the upstream manufacturing processes essential for gene therapy, cell therapy, mRNA vaccines, and next-generation biologics. It includes the production of high-purity, high-expression plasmid DNA and the preparation of high-titer, functionally stable viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). These processes must be conducted under stringent GMP conditions, often using microbial or mammalian expression systems, and involve key steps such as fermentation, purification, quality control, and encapsulation. With the rapid advancement of biotechnology, this sector is evolving from lab-scale production to industrial-scale manufacturing, becoming a strategic focus for CDMOs and biotech firms worldwide.In this report, we only study the Viral Vector and Plasmid DNA used for research.
    As the commercialization of cell and gene therapies accelerates, global demand for viral vectors and plasmid DNA continues to grow. An increasing number of CAR-T therapies, AAV-based gene therapies, and mRNA vaccine programs are advancing into clinical and commercial stages, positioning high-quality vector materials as critical bottleneck resources. Meanwhile, supportive government policies promoting the localization of gene therapy and vaccine production are driving investment in GMP-compliant vector platforms. The expanding CDMO market, stronger outsourcing trends among biotech companies, and process optimization efforts lowering production costs are jointly propelling this sector toward rapid development.
    Despite strong demand, the sector faces technical and regulatory hurdles. Standardization remains limited, with cross-platform consistency in production still difficult to achieve. The bar for quality control is high, requiring strict management of viral safety, residual nucleic acids, and encapsulation efficiency. Moreover, premium GMP capacity is still dominated by a few multinational firms, while emerging players often face challenges in infrastructure investment, technical expertise, and talent acquisition. Regulatory scrutiny is also intensifying, lengthening development timelines and raising entry thresholds.
    Clinical pipeline expansion and commercial product launches are the primary growth drivers for this field. In indications such as rare diseases, cancer immunotherapy, and neurological disorders, the use of AAV and lentiviral vectors is increasing significantly. At the same time, plasmid DNA is widely used as a starting template or precursor for mRNA, vaccines, nucleic acid drugs, and CRISPR-based therapies. Strategic partnerships between pharma and CDMO players are proliferating to develop modular, scalable manufacturing platforms that can support a diverse array of downstream applications.
    This report is a detailed and comprehensive analysis for global Viral Vector and Plasmid DNA market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Viral Vector and Plasmid DNA market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Viral Vector and Plasmid DNA market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Viral Vector and Plasmid DNA market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Viral Vector and Plasmid DNA market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Viral Vector and Plasmid DNA
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Viral Vector and Plasmid DNA market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Lonza, Azenta Life Sciences, Revvity, VectorBuilder, Takara Bio, GenScript Biotech, Gene Chem, Geno Meditech, PackGene Biotech, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Viral Vector and Plasmid DNA market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    AAV
    Lentiviruses
    Retroviruses
    Adenoviruses
    DNA Plasmids
    Other
    Market segment by Application
    Pharmaceutical and Biopharmaceutical Companies
    Academics and Research Institutes
    Market segment by players, this report covers
    Thermo Fisher Scientific
    Lonza
    Azenta Life Sciences
    Revvity
    VectorBuilder
    Takara Bio
    GenScript Biotech
    Gene Chem
    Geno Meditech
    PackGene Biotech
    VIROVEK
    OriGen
    Vector BioLabs
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Viral Vector and Plasmid DNA product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Viral Vector and Plasmid DNA, with revenue, gross margin, and global market share of Viral Vector and Plasmid DNA from 2021 to 2026.
    Chapter 3, the Viral Vector and Plasmid DNA competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Viral Vector and Plasmid DNA market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector and Plasmid DNA.
    Chapter 13, to describe Viral Vector and Plasmid DNA research findings and conclusion.

    Buy now